menu
    • menu
    [{"orgOrder":0,"company":"Earendil Labs","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"HXN-1002","moa":"Alpha-4-beta-7\/TL1A","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Earendil Labs","amount2":1.8500000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":1.8500000000000001,"dosageForm":"Undisclosed","sponsorNew":"Earendil Labs \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Earendil Labs \/ Sanofi"},{"orgOrder":0,"company":"Earendil Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"HXN-1001","moa":"TL1A","graph1":"Immunology","graph2":"Phase I","graph3":"Earendil Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Earendil Labs \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Earendil Labs \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Earendil Labs

    Menu

    Earendil Labs

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Earendil Labs

                            U.S.A arrow
                            ACS Fall 2025
                            Not Confirmed

                            Earendil Labs

                            U.S.A arrow
                            ACS Fall 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HXN-1001

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Earendil Starts Phase 1 Trial for Half-Life Extended Anti-TL1A Antibody

                            Details : HXN-1001 is a half-life extended next-generation anti-TL1A antibody with great potential for the treatment of patients with IBD, including ulcerative colitis and Crohn's disease.

                            Product Name : HXN-1001

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            July 11, 2025

                            Lead Product(s) : HXN-1001

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Earendil Labs

                            U.S.A arrow
                            ACS Fall 2025
                            Not Confirmed

                            Earendil Labs

                            U.S.A arrow
                            ACS Fall 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HXN-1002

                            Therapeutic Area : Gastroenterology

                            Study Phase : Preclinical

                            Sponsor : Sanofi

                            Deal Size : $1,845.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Earendil Labs Licenses Bispecific Antibodies for Autoimmune use from Sanofi

                            Details : Under the licensing agreement, Sanofi will obtain exclusive worldwide rights to antibody, HXN-1002. It is designed to provide a treatment option for patients with ulcerative colitis.

                            Product Name : HXN-1002

                            Product Type : Antibody

                            Upfront Cash : $125.0 million

                            April 17, 2025

                            Lead Product(s) : HXN-1002

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Preclinical

                            Sponsor : Sanofi

                            Deal Size : $1,845.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth